Cargando…
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
BACKGROUND: A phasic dysregulation of mitochondrial bioenergetics may operate in bipolar disorder, increased in mania and decreased in depression. We aimed to examine efficacy of two add-on treatments in bipolar depression: N-acetylcysteine (NAC) and NAC with a combination of nutraceutical agents th...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346513/ https://www.ncbi.nlm.nih.gov/pubmed/30678686 http://dx.doi.org/10.1186/s12916-019-1257-1 |
_version_ | 1783389766863028224 |
---|---|
author | Berk, Michael Turner, Alyna Malhi, Gin S. Ng, Chee Cotton, Susan M. Dodd, Seetal Samuni, Yuval Tanious, Michelle McAulay, Claire Dowling, Nathan Sarris, Jerome Owen, Lauren Waterdrinker, Astrid Smith, Deidre Dean, Olivia M. |
author_facet | Berk, Michael Turner, Alyna Malhi, Gin S. Ng, Chee Cotton, Susan M. Dodd, Seetal Samuni, Yuval Tanious, Michelle McAulay, Claire Dowling, Nathan Sarris, Jerome Owen, Lauren Waterdrinker, Astrid Smith, Deidre Dean, Olivia M. |
author_sort | Berk, Michael |
collection | PubMed |
description | BACKGROUND: A phasic dysregulation of mitochondrial bioenergetics may operate in bipolar disorder, increased in mania and decreased in depression. We aimed to examine efficacy of two add-on treatments in bipolar depression: N-acetylcysteine (NAC) and NAC with a combination of nutraceutical agents that may increase mitochondrial biogenesis. METHODS: A three-arm 16-week, double-blind, randomised, placebo-controlled trial, adjunctive to usual treatment, was conducted. Participants (n = 181) with bipolar disorder and current depressive symptoms were randomised to 2000 mg/day NAC (n = 59), 2000 mg/day NAC with the combination nutraceutical treatment (CT, n = 61), or placebo (n = 61). The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 16. Young Mania Rating Scale, Clinical Global Impression (CGI)-Improvement and CGI-Severity scales, Patient Global Impression scale, Social and Occupational Functioning Assessment Scale (SOFAS), Longitudinal Interval Follow-Up Evaluation - Range of Impaired Functioning Tool (LIFE-RIFT), and Quality of Life Enjoyment, and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) were secondary outcomes. RESULTS: One hundred forty-eight participants had post-randomisation data and were analysed (NAC = 52, CT = 47, Placebo = 49). No between-group differences were found for the rate of change between baseline and 16 weeks on any of the clinical and functioning variables. Improvements in MADRS, BDRS, SOFAS, and LIFE-RIFT scores from baseline to the week 20 post-discontinuation visit were significantly greater in the CT group compared to those in the placebo. At week 20, the CGI-I was significantly lower in the CT group versus placebo. Gastrointestinal symptoms were significantly greater in the NAC than in the placebo group. CONCLUSIONS: These overall negative results, with no significant differences between groups detected at the primary outcome but some positive secondary signals, suggest either delayed benefit of the combination or an improvement of symptoms on withdrawal which warrants further exploration regarding the composition, mechanisms, and application of mitochondrial agents in illnesses characterised by mitochondrial dysfunction. TRIAL REGISTRATION: ANZCTR (ACTRN12612000830897). |
format | Online Article Text |
id | pubmed-6346513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63465132019-01-29 A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo Berk, Michael Turner, Alyna Malhi, Gin S. Ng, Chee Cotton, Susan M. Dodd, Seetal Samuni, Yuval Tanious, Michelle McAulay, Claire Dowling, Nathan Sarris, Jerome Owen, Lauren Waterdrinker, Astrid Smith, Deidre Dean, Olivia M. BMC Med Research Article BACKGROUND: A phasic dysregulation of mitochondrial bioenergetics may operate in bipolar disorder, increased in mania and decreased in depression. We aimed to examine efficacy of two add-on treatments in bipolar depression: N-acetylcysteine (NAC) and NAC with a combination of nutraceutical agents that may increase mitochondrial biogenesis. METHODS: A three-arm 16-week, double-blind, randomised, placebo-controlled trial, adjunctive to usual treatment, was conducted. Participants (n = 181) with bipolar disorder and current depressive symptoms were randomised to 2000 mg/day NAC (n = 59), 2000 mg/day NAC with the combination nutraceutical treatment (CT, n = 61), or placebo (n = 61). The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 16. Young Mania Rating Scale, Clinical Global Impression (CGI)-Improvement and CGI-Severity scales, Patient Global Impression scale, Social and Occupational Functioning Assessment Scale (SOFAS), Longitudinal Interval Follow-Up Evaluation - Range of Impaired Functioning Tool (LIFE-RIFT), and Quality of Life Enjoyment, and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) were secondary outcomes. RESULTS: One hundred forty-eight participants had post-randomisation data and were analysed (NAC = 52, CT = 47, Placebo = 49). No between-group differences were found for the rate of change between baseline and 16 weeks on any of the clinical and functioning variables. Improvements in MADRS, BDRS, SOFAS, and LIFE-RIFT scores from baseline to the week 20 post-discontinuation visit were significantly greater in the CT group compared to those in the placebo. At week 20, the CGI-I was significantly lower in the CT group versus placebo. Gastrointestinal symptoms were significantly greater in the NAC than in the placebo group. CONCLUSIONS: These overall negative results, with no significant differences between groups detected at the primary outcome but some positive secondary signals, suggest either delayed benefit of the combination or an improvement of symptoms on withdrawal which warrants further exploration regarding the composition, mechanisms, and application of mitochondrial agents in illnesses characterised by mitochondrial dysfunction. TRIAL REGISTRATION: ANZCTR (ACTRN12612000830897). BioMed Central 2019-01-25 /pmc/articles/PMC6346513/ /pubmed/30678686 http://dx.doi.org/10.1186/s12916-019-1257-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Berk, Michael Turner, Alyna Malhi, Gin S. Ng, Chee Cotton, Susan M. Dodd, Seetal Samuni, Yuval Tanious, Michelle McAulay, Claire Dowling, Nathan Sarris, Jerome Owen, Lauren Waterdrinker, Astrid Smith, Deidre Dean, Olivia M. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo |
title | A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo |
title_full | A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo |
title_fullStr | A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo |
title_full_unstemmed | A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo |
title_short | A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo |
title_sort | randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, n-acetylcysteine, and placebo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346513/ https://www.ncbi.nlm.nih.gov/pubmed/30678686 http://dx.doi.org/10.1186/s12916-019-1257-1 |
work_keys_str_mv | AT berkmichael arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT turneralyna arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT malhigins arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT ngchee arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT cottonsusanm arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT doddseetal arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT samuniyuval arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT taniousmichelle arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT mcaulayclaire arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT dowlingnathan arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT sarrisjerome arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT owenlauren arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT waterdrinkerastrid arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT smithdeidre arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT deanoliviam arandomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT berkmichael randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT turneralyna randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT malhigins randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT ngchee randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT cottonsusanm randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT doddseetal randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT samuniyuval randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT taniousmichelle randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT mcaulayclaire randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT dowlingnathan randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT sarrisjerome randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT owenlauren randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT waterdrinkerastrid randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT smithdeidre randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo AT deanoliviam randomisedcontrolledtrialofamitochondrialtherapeutictargetforbipolardepressionmitochondrialagentsnacetylcysteineandplacebo |